A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Hummingbird Bioscience
Hummingbird Bioscience
University of Cincinnati
Bristol-Myers Squibb
University of California, San Francisco
Janssen Research & Development, LLC
Genmab
DualityBio Inc.
University of Colorado, Denver
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
Amgen
Aulos Bioscience, Inc.
Ipsen
Radiopharm Theranostics, Ltd
Terremoto Biosciences Inc.
Taiho Oncology, Inc.
Ensem Therapeutics
AstraZeneca
Mayo Clinic
West China Hospital
Tubulis GmbH
Alentis Therapeutics AG
Eli Lilly and Company
Neonc Technologies, Inc.
Sumitomo Pharma America, Inc.
University of Washington
NYU Langone Health
Merus B.V.
Tasca Therapeutics
Memorial Sloan Kettering Cancer Center
Exscientia AI Limited
Amgen
University of California, Davis
Grey Wolf Therapeutics
One-carbon Therapeutics AB
Xinqiao Hospital of Chongqing
Transgene
Onchilles Pharma Inc
Ocellaris Pharma, Inc.
Washington University School of Medicine
Kura Oncology, Inc.
Inhibrx Biosciences, Inc
M.D. Anderson Cancer Center
VM Oncology, LLC
Tanabe Pharma America, Inc.
Takeda
DualityBio Inc.
BicycleTx Limited
Roswell Park Cancer Institute
University of Pittsburgh